PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DNA methylation is aberrantly regulated in chronic lymphocytic leukemia. This pilot study aims to find the dose of Vidaza that will inhibit global DNA methylation by 20%. We previously showed that inhibition of global DNA methylation by 20% in patients after treatment with decitabine re-expressed MAGE-1, a tumor antigen previously silenced by DNA methylation. Once we find the lowest dose of Vidaza which inhibits DNA methylation and re-expresses MAGE-1, we may be able to combine Vidaza with drugs like alkylators, proteasome inhibitors, monoclonal antibodies and make chronic lymphocytic leukemia more sensitive to chemotherapy.